CERS News and Press, Cerus Corporation From 05/04/20

Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The planned conversion to these new kits is part of the Company’s ongoing strategy to enhance its global supply chain integrity th...

Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have initiated a clinical trial evaluating the efficacy of convalescent plasma in COVID-19 patients. More news on: XBiotech Inc., Cerus Corporation, ThermoGenesis Holdings, Inc., Healthcare stocks news, Stocks ...

Cerus Corporation (Nasdaq:CERS) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss...

Cerus (NASDAQ: CERS ) amends its contract with the Biomedical Advanced Research and Development Authority (BARDA). More news on: Cerus Corporation, Healthcare stocks news, Read more ...

Cerus Corporation (Nasdaq:CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The amendment provides an additional $14 million in available funding, increasing the total potential value of the contract to...

Gainers: UAL   +7.5% .   PVAC   +6.7% . AAL   +6.7% . GME   +6.6%.  FHN   +5.9% . More news on: United Airlines Holdings, Inc., Penn Virginia Corporation, American Airlines Group Inc., Stocks on the move, , Read more ...

In the midst of the Coronavirus Crash, there have been several small-cap companies that have experienced a surge in attention and in their stock's share price. Many of these tickers are healthcare companies that are attempting to develop vaccines, antivirals, devices, or therapeutics to combat...

Cerus Corporation (Nasdaq:CERS) today announced the Company’s recent activities related to COVID-19 and efforts to ensure that patients have readily available access to pathogen-reduced blood components, including convalescent plasma. “As the world endures the impact from th...

Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled “ Points to consider in the preparation and transfusion of COVID-19 convalescent plasma .” The document w...

Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP). Cerus’ field team supported the INTERCEPT system implementation which was completed in one week. ...